Thyme Care combines oncology-trained care teams and technology to support people through cancer treatment while helping health plans and providers improve outcomes and control costs. It monitors patient needs between appointments, coordinates with oncologists and connects members to clinical, practical and social support.
FC
Foresite Capital
Activity from announced rounds
Activity in this selectionOct 17, 2026 · Jul 20, 2026
Foresite Capital is a healthcare investment firm identified by Abcuro and in its own Thyme Care portfolio record.
Recorded funding activity
Abcuro develops immunotherapies targeting pathogenic cytotoxic T cells. Thyme Care combines oncology care teams with technology, while Khartis develops oral medicines for immune and chronic diseases. The company histories distinguish care delivery from experimental drug development.
- Rounds participated in
- 3
- Confirmed lead rounds
- 0 2 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $116M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionThyme Care
>$125MSeries E
ParticipantAbcuro
Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.
$66MSeries D
Role not disclosedKhartis Therapeutics
Develops oral small molecule therapies for immunological and chronic diseases
$50MSeries B
Role not disclosed